Chromogranin A cells in the stomachs of patients with sporadic irritable bowel syndrome

El-Salhy,Magdy; Gilja,Odd  Helge; Hausken,Trygve

doi:10.3892/mmr.2014.2472

Chromogranin A cells in the stomachs of patients with sporadic irritable bowel syndrome

Authors:
- Magdy El-Salhy
- Odd Helge Gilja
- Trygve Hausken
View Affiliations

Affiliations: Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord 54 09, Norway, Section for Gastroenterology, Department of Clinical Medicine, University of Bergen, Bergen 5020, Norway
Published online on: August 8, 2014 https://doi.org/10.3892/mmr.2014.2472
Pages: 1753-1757
Copyright: © El-Salhy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several abnormalities have been demonstrated in the intestines of patients with irritable bowel syndrome (IBS); however, the endocrine cells in the stomachs of these patients have not been investigated. The aim of the present study was to determine whether there are any abnormalities in the endocrine cells of the stomachs of patients with IBS using chromogranin A (CgA) as a common marker for endocrine cells. A total of 76 patients were included, of which 26 presented with diarrhoea as the predominant symptom (IBS‑D), 21 exhibited diarrhoea and constipation (IBS‑M), and 29 experienced constipation as the predominant symptom (IBS‑C). In addition, 59 healthy volunteers were recruited as controls. The patients and the controls underwent gastroscopy, and biopsy samples were obtained from the antrum and corpus of the stomach. The biopsy samples were immunostained and the CgA‑positive cell density and the intensity of the CgA immunoreactivity were determined. The CgA‑positive cell densities in the antra of patients with IBS‑M were significantly reduced relative to the controls (P<0.01), while the densities were significantly increased in the antra and corpora of the IBS‑C patients (P<0.01 and P<0.001 respectively). The intensities of CgA immunoreactivity did not differ significantly between the IBS patients and the controls. The abnormalities in the densities of endocrine cells were not associated with concomitant changes in the intensities of immunoreactivity; this may indicate unchanged synthesis and/or release of the hormones. In conclusion, the difference in the density of endocrine cells among the IBS subtypes may reflect a role of these cells in the differential symptomologies of these subtypes.

View Figures

View References

1	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers Inc.; New York, NY: 2012
2	Spiller RC: Potential biomarkers. Gastroenterol Clin North Am. 40:121–139. 2011. View Article : Google Scholar
3	Spiller R, Aziz Q, Creed F, et al; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 56:1770–1798. 2007. View Article : Google Scholar : PubMed/NCBI
4	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
5	Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1569–1580. 1993. View Article : Google Scholar
6	Thompson WG: A world view of IBS. Irritable bowel syndrome: diagnosis and treatment. Camilleri M and Spiller RC: Saunders; Philadelphia: pp. 17–26. 2002
7	Harvey RF, Mauad EC and Brown AM: Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet. 1:963–965. 1987.PubMed/NCBI
8	Nørgaard M, Farkas DK, Pedersen L, et al: Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer. 104:1202–1206. 2011.PubMed/NCBI
9	Taupenot L, Harper KL and O’Connor DT: The chromogranin-secretogranin family. N Engl J Med. 348:1134–1149. 2003. View Article : Google Scholar : PubMed/NCBI
10	Wiedenmann B and Huttner WB: Synaptophysin and chromogranins/secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121. 1989. View Article : Google Scholar
11	Deftos LJ: Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 12:181–187. 1991. View Article : Google Scholar : PubMed/NCBI
12	El-Salhy M, Lomholt-Beck B and Hausken T: Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010. View Article : Google Scholar : PubMed/NCBI
13	El-Salhy M, Mazzawi T, Gundersen D and Hausken T: Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Report. 6:1223–1225. 2012.PubMed/NCBI
14	El-Salhy M, Wendelbo IH and Gundersen D: Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep. 7:1241–1244. 2013.PubMed/NCBI
15	El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800. 2012. View Article : Google Scholar : PubMed/NCBI
16	El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG and Hausken T: The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med. 29:723–731. 2012.PubMed/NCBI
17	El-Salhy M and Mahdavi J: Image analysis of the duodenal endocrine cells in mice with particular regard to optic densitomertry. Uppsala J Med Sci. 102:175–184. 1997. View Article : Google Scholar : PubMed/NCBI
18	El-Salhy M: Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). Int J Mol Med. 24:727–732. 2009. View Article : Google Scholar : PubMed/NCBI
19	El-Salhy M, Lillebø E, Reinemo A and Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
20	Dizdar V, Spiller R, Singh G, et al: Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 31:883–891. 2010.
21	El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010. View Article : Google Scholar : PubMed/NCBI
22	El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
23	El-Salhy M, Gundersen D, Hatlebakk JG, Gilja OH and Hausken T: Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept. 188:60–65. 2014. View Article : Google Scholar : PubMed/NCBI
24	Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar
25	Wang SH, Dong L, Luo JY, et al: Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar
26	Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK and Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
27	Park JH, Rhee PL, Kim G, et al: Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006. View Article : Google Scholar
28	Kim HS, Lim JH, Park H and Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J. 51:45–51. 2010.
29	Dunlop SP, Coleman NS, Blackshaw E, et al: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 3:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
30	Spiller RC, Jenkins D, Thornley JP, et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811. 2000. View Article : Google Scholar
31	Wang LH, Fang XC and Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 53:1096–1101. 2004. View Article : Google Scholar : PubMed/NCBI
32	Dunlop SP, Jenkins D, Neal KR and Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 125:1651–1659. 2003. View Article : Google Scholar : PubMed/NCBI